Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)

被引：0
|
作者：
Eckardt, J
Depierre, A
Ardizzoni, A
VonPawel, J
Fields, S
机构：
[1] ST JOHNS MERCY HOSP,ST LOUIS,MO
[2] HOP ST JACQUES,F-25030 BESANCON,FRANCE
[3] ZENT KRANKENHAUS GAUTING,D-82131 GAUTING,GERMANY
[4] SMITHKLINE BEECHAM PHARMACEUT,COLLEGEVILLE,PA 19426
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1041 / 1041
页数：1
相关论文
共 50 条
  • [31] Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer
    Wakuda, Kazushige
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Takahashi, Toshiaki
    IN VIVO, 2019, 33 (06): : 2229 - 2234
  • [32] A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC)
    Kontopodis, E.
    Vamvakas, L.
    Kalbakis, K.
    Vardakis, N. K.
    Sfakiotaki, G.
    Georgoulias, V.
    Agelaki, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Optimal drugs for second-line treatment of patients with small-cell lung cancer
    Rossi, Antonio
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Santabarbara, Giuseppe
    Palazzolo, Giovanni
    Maione, Paolo
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 969 - 976
  • [34] Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study
    Du, Yang
    Liu, Xiao-Yan
    Si, Xiao-Yan
    Zhang, Xiao-Tong
    Zhou, Jing-Ya
    Wang, Yi
    Chen, Min-Jiang
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07)
  • [35] Topotecan in Second-Line Treatment of Small-Cell Lung Cancer -How it Works in Our Daily Clinical Practice?
    Lourenco Moreira Faria, Ana Luisa
    Bravo, Emilio Macias
    Silva Soares Rocha, Marta Alexandra
    Azevedo Rocha, Isabel Maria
    Pequeno Coelho, Ana Luisa
    Ferreira Araujo, Antonio Manuel
    CURRENT DRUG SAFETY, 2010, 5 (02) : 114 - 117
  • [36] New Advances in the Second-Line Treatment of Small Cell Lung Cancer
    Hurwitz, Jane L.
    McCoy, Francis
    Scullin, Paula
    Fennell, Dean A.
    ONCOLOGIST, 2009, 14 (10): : 986 - 994
  • [37] Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials
    Spigel, D. R.
    Shah, C.
    Lorigan, P.
    McNally, R.
    Renschler, M.
    Oliver, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)
    Ardizzoni, A
    Hansen, HH
    Dombernowsky, P
    Kaplan, S
    Postmus, PE
    Gamucci, T
    Schaefer, B
    Wanders, J
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 84 - 84
  • [39] Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis
    Lopez Jimenez, A.
    Esquerdo, G.
    Barrajon, E.
    Del Rio Pazos, L.
    Cervera, J.
    Diaz, N.
    Angeles Oyonarte, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Weekly CPT-11 as second line treatment for small cell lung cancer (SCLC) patients
    Juan, Oscar
    Munoz, Jose
    Esquerdo, Gaspar
    Sanchez, Alfredo
    Galan, Antonio
    Albert, Ana
    Munarriz, Javier
    Llorca, Cristina
    Almenar, Daniel
    ANNALS OF ONCOLOGY, 2004, 15 : 191 - 191
12345